In the Driver’s Seat With EGFR: Application of Mutation Testing to Treatment Selection for NSCLC

Identifying Actionable Markers to Guide Therapy for Patients With EGFR-Mutant NSCLC


With over 55% of cancer patients treated by community oncologists, it’s imperative that community oncologists and pathologists apply a multidisciplinary team approach to caring for patients. As precision medicine continues to evolve in cancer care, the integration of pathologists within clinical care pathways to interpret test results and offer recommendations for biomarker testing aid in personalized treatment approaches.

This series offers two interactive programs supported by audio and video commentary, where expert faculty share insights on molecular testing recommendations, guidance on interpreting molecular testing results, and clinical trial evidence in order to help clinicians:
• Increase implementation of best practices for EGFR mutation testing in patients with NSCLC
• Apply clinical trial data to treatment selection in patients with EGFR-mutant NSCLC
• Understand the role of concurrent mutations, such as TP53, in the prognosis and response to therapy of patients with EGFR-mutant NSCLC


Access the interactive infographic, case study, and claim credit: